Terms: = Kidney tumors AND IL6ST, CDw130, 3572, ENSG00000134352, P40189, IL6R-beta, GP130-RAPS, GP130, CD130 AND Treatment
6 results:
1. The levels of IL-6 and soluble IL-33R are increased in the renal vein during surgery for clear cell renal cell carcinoma.
Gudbrandsdottir G; Aarstad HH; Hjelle KM; Førde K; Reisæter L; Bostad L; Aarstad HJ; Beisland C
Cytokine; 2021 Aug; 144():155586. PubMed ID: 34058568
[TBL] [Abstract] [Full Text] [Related]
2. Interleukin-6 as an emerging regulator of renal cell cancer.
Kamińska K; Czarnecka AM; Escudier B; Lian F; Szczylik C
Urol Oncol; 2015 Nov; 33(11):476-85. PubMed ID: 26296264
[TBL] [Abstract] [Full Text] [Related]
3. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
Suchorska WM; Dams-Kozlowska H; Kazimierczak U; Wysocki PJ; Mackiewicz A
Expert Opin Biol Ther; 2011 Dec; 11(12):1555-67. PubMed ID: 21995459
[TBL] [Abstract] [Full Text] [Related]
4. STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P.
Horiguchi A; Oya M; Marumo K; Murai M
Kidney Int; 2002 Mar; 61(3):926-38. PubMed ID: 11849447
[TBL] [Abstract] [Full Text] [Related]
5. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.
Lu ZY; Brailly H; Wijdenes J; Bataille R; Rossi JF; Klein B
Blood; 1995 Oct; 86(8):3123-31. PubMed ID: 7579407
[TBL] [Abstract] [Full Text] [Related]
6. Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma.
de Mulder PH; Debruyne FM; Franssen MP; Geboers AD; Strijk S; Reintjes AG; Doesburg WH; Damsma O
Cancer Immunol Immunother; 1990; 31(5):321-4. PubMed ID: 2115817
[TBL] [Abstract] [Full Text] [Related]
